Living Cell Technologies Receives 10% of CytoSolv

Living Cell Technologies Limited

Living Cell Technologies Receives 10% of US Based Wound Healing Company in Supply and Licence Agreement

9 February 2010: Sydney, Australia, Auckland, New Zealand – Cell implant company Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that it has received 10% ownership of CytoSolv Inc. in exchange for restricted supply of choroid plexus cell clusters from its designated pathogen free pig herd and granting CytoSolv a non-exclusive, non-transferable licence to use its broad choroid plexus patents solely for the purpose of wound healing.

CytoSolv is a newly formed Rhode Island biomedical company developing proprietary technology to address wound healing, initially targeting diabetic ulcers. Its technology involves the delivery of a mixture of wound-healing factors derived from porcine choroid plexus (CP) cells cultured using proprietary techniques. These cells normally secrete a variety of factors into the cerebrospinal fluid that are responsible for growth, differentiation, nurturing and maintenance of the brain. CytoSolv has demonstrated that a topical gel based on a cocktail of these factors accelerates and improves the quality of healing of open skin wounds, and has recently been awarded USD500,000 from the Slater Technology Fund to pursue more advanced pre-clinical development in the year ahead.

Dr Paul Tan, Chief Executive Officer LCT said: “Although this collaboration is outside LCT’s core business of live cell implants, the topical use of secreted products from porcine CP cells offers a potential revenue stream from supply of cells and investment return. The experienced team at CytoSolv has produced very promising preliminary data, and we look forward to continuing this exciting collaboration.”

Ends

© Scoop Media